<!DOCTYPE html>
<html class="theme-sleek astro-STCLZLJ5" lang="en">
  <head>
    <!-- Global Metadata -->
    <meta charset="utf-8">
    <meta name="viewport" content="width=device-width,initial-scale=1">
    <meta name="theme-color" media="(prefers-color-scheme: light)" content="#ffffff">
<meta name="theme-color" media="(prefers-color-scheme: dark)" content="#18181b">
<!-- 
  This is an example. 
  Use https://realfavicongenerator.net to generate the icons and manifest. 
-->
<link href="/favicon.ico" rel="shortcut icon">

    <!-- Primary Meta Tags --><title>Biased Type 1 Cannabinoid Receptor Signalling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.</title>
<meta name="title" content="Biased Type 1 Cannabinoid Receptor Signalling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.">
<meta name="description" content="Medical Cannabis Awareness New Zealand">


<!-- Open Graph / Facebook -->
<meta property="og:title" content="Biased Type 1 Cannabinoid Receptor Signalling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.">
<meta property="og:description" content="Medical Cannabis Awareness New Zealand">
<meta property="og:type" content="article">
<meta property="og:url" content="https://mcanz.org.nz/blog/biased-type-1-cannabinoid-receptor-signalling-influences-neuronal-viability-in-a-cell-culture-model-of-huntington-disease">

<meta property="article:published_time" content="2016-01-11T00:00:00.000Z">





<!-- Twitter -->
<meta property="twitter:title" content="Biased Type 1 Cannabinoid Receptor Signalling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.">
<meta property="twitter:description" content="Medical Cannabis Awareness New Zealand">


<meta property="twitter:card" content="summary_large_image">


<!-- {twitter.url && <meta property="twitter:url" content={twitter.url} />} -->

  <link rel="stylesheet" href="/assets/_slug_.2607fc28.css" />
<link rel="stylesheet" href="/assets/_slug_.f022e152.css" /></head>

  <body class="text-text-body bg-bg-body max-w-3xl mx-auto px-4 sm:px-8 astro-STCLZLJ5">
    <header class="astro-FAM4J5CX">
  <a class="skip-to-main astro-FAM4J5CX" href="#main"> Skip to content</a>
  <nav class="astro-FAM4J5CX">
    <section class="astro-FAM4J5CX">
      <ul class="astro-FAM4J5CX">
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/" class="astro-FAM4J5CX header-link unset animated gradient-colors astro-C675TBRQ">Home</a>
</li>
        <li class="astro-FAM4J5CX"><!-- DO NOT FORMAT. IT ADDS AN EXTRA SPACE ON RENDERED CONTENT. --><a href="/blog" class="astro-FAM4J5CX active header-link unset animated gradient-colors astro-C675TBRQ">Blog</a>
</li>
      </ul>
    </section>
  </nav>
</header>

    <main id="main" class="astro-STCLZLJ5">
      <section class="blog-post astro-STCLZLJ5">
        <h1 class="title astro-STCLZLJ5">Biased Type 1 Cannabinoid Receptor Signalling Influences Neuronal Viability in a Cell Culture Model of Huntington Disease.</h1>
        <time class="publish-date astro-STCLZLJ5">Jan 11, 2016</time>
        <article><p>Author: <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Laprairie%20RB%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26700564">Laprairie RB</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Bagher%20AM%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26700564">Bagher AM</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Kelly%20ME%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26700564">Kelly ME</a>, <a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Denovan-Wright%20EM%5BAuthor%5D&#38;cauthor=true&#38;cauthor_uid=26700564">Denovan-Wright EM</a>.</p><h3>Abstract</h3><p>Huntington disease (HD) is an inherited, autosomal dominant, neurodegenerative disorder with limited treatment options. Prior to motor symptom onset or neuronal cell loss in HD, levels of the type 1 cannabinoid receptor (CB1) decrease in the basal ganglia. Decreasing CB1 levels are strongly correlated with chorea and cognitive deficit. CB1 agonists are functionally selective (biased) for divergent signalling pathways. In this study, sixcannabinoids were tested for signalling bias in in vitro models of medium spiny projection neurons expressing wild-type (STHdhQ7/Q7) or mutant huntingtin protein (STHdhQ111/Q111). Signalling bias was assessed using the Black and Leff operational model. Relative activity [ΔlogR (τ;/KA)] and system bias (ΔΔlogR) were calculated relative to the reference compound WIN55,212-2 for Gα;i/o, Gαs, Gαq, Gβγ, and β-arrestin1 signalling following treatment with 2-arachidonoylglycerol (2-AG), anandamide (AEA), CP55,940, Δ9-tetrahydrocannabinol (THC), cannabidiol (CBD), and THC+CBD (1:1) and compared between wild-type and HD cells. The Emax of Gαi/o-dependent ERK signalling was 50% lower in HD cells compared to wild-type cells. 2-AG and AEA displayed Gαi/o/Gβγ bias and normalized CB1 protein levels and improved cell viability, whereas CP55,940 and THC displayed β-arrestin1 bias and reduced CB1 protein levels and cell viability, in HD cells. CBD was not a CB1 agonist, but inhibited THC-dependent signalling (THC+CBD). Therefore, enhancing Gαi/o-biased endocannabinoid signalling may be therapeutically beneficial in HD. In contrast, cannabinoids that are β-arrestin-biased - such as THC found at high levels in modern varieties of marijuana - may be detrimental to CB1 signalling, particularly in HD where CB1 levels are already reduced.</p><p>The American Society for Pharmacology and Experimental Therapeutics.</p></article>
      </section>
    </main>
    <footer class="astro-5AYKG27L">
  <div class="astro-5AYKG27L">

  </div>
</footer>


  
</body>


</html>